Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers

sigma-tau i.f.r. S.p.A.37 enrolled

Overview

The study was designed to assess the effect of food on the extent and rate of absorption of Dihydroartemisinin (DHA) and Piperaquine Phosphate (PQP) administered as a fixed dose combination (Eurartesim™).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Malaria, Falciparum

Interventions

EurartesimDRUG

Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Caucasian healthy males aged between 18 and 50 years(inclusive). * Body Mass Index (BMI) between 19.0 kg/m2 and 27.0 kg/m2 inclusive, with a minimum body weight of 75 kg. * Agreed to use two approved methods of contraception from Screening and until 90 days after administration of the study drug * Had given written informed consent to participate in this study in accordance with local regulations. Exclusion Criteria: * Had received or was anticipated to receive a prescription medication within 14 days prior to the start of dosing or an over-the-counter medicine 48 hours prior to the start of dosing. * Abnormal laboratory test results deemed clinically significant by the Medical Officer. * Positive urine drug test (e.g. opiates and cannabinoids) or alcohol breath test. * History of significant drug allergies or significant allergic reaction. * Receipt of blood or blood products, or loss or donation of 450 mL or more of blood within 90 days before the first dose administration.

Locations (1)

CMAX, a division of IDT Australia Limited

Adelaide, Australia

Outcomes

Primary Outcomes

tmax, Cmax, AUC0-last, AUC0-24 [PQ], and AUC0-inf, λz, t1/2, Cl/F, Vz/F [DHA].

Blood samples for determination of plasma DHA were collected at the following times: At pre-dose Day 0 and then at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours post-dose. Blood samples for determination of plasma PQ were collected at the following times: At pre-dose Day 0 and then at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose; on Day 1, 2, 3, 4, 5 and 7.

Time frame: from the day of study drug administration, till Day 7 follow-up

Secondary Outcomes

Number of Treatment Emergent Adverse Events

Number of TEAEs and number of Subjects experiencing Adverse Events during all the study period

Time frame: Day 0 and till Day 30 follow-up

Hematology and blood chemistry changes respect to baseline values

Abnormalities in hematology (Haemoglobin, Hematocrit,RBC count, White cell count and differential count, Platelets) and clinical chemistry (Protein, Sodium, Potassium, Chloride ,Total Bilirubin, Conjugated Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Total Cholesterol, Glucose, Bicarbonate, Urea, Urate, Lactate Dehydrogenase, Albumin, Globulins, Triglycerides, Creatinine, Alkaline Phosphatase, Gamma glutamyltransferase, Total Calcium, Phosphate, C-reactive protein) will be recorded the day of the last study drug intake and after 30 days from the start of the drug treatment

Time frame: Day 0, day 2, day 30

QTc interval prolongation

ECG recordings will be obtained at baseline, after the last drug intake and 30 days follow-up to investigate changes in ECG parameters, and specifically QTc interval changes respect to baseline

Time frame: Day 0, day 2, day 30

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.